Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?
about
A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United StatesA perspective on the role of estrogen in hormone-induced prostate carcinogenesisCharacterization of the equine skeletal muscle transcriptome identifies novel functional responses to exercise trainingGene doping in sport - perspectives and risksThe effects of mechanical loading on tendons--an in vivo and in vitro model studyDietary fat, fiber, and carbohydrate intake and endogenous hormone levels in premenopausal womenHormones and prostate carcinogenesis: Androgens and estrogens.Age-related decline in immunity: implications for vaccine responsiveness.Serum reference value of two potential doping candidates-myostatin and insulin-like growth factor-I in the healthy young male.Doping and musculoskeletal system: short-term and long-lasting effects of doping agents.Obesity-related colon cancer: dietary factors and their mechanisms of anticancer action.Impact of physical activity and doping on epigenetic gene regulation.Doping in sport and exercise: anabolic, ergogenic, health and clinical issues.Equine performance genes and the future of doping in horseracing.Darbepoetin inhibits proliferation of hepatic cancer cells in the presence of TGF-β.Currently neglected, physical examination maintains its clinical relevance.Influence of Intramuscular Application of Autologous Conditioned Plasma on Systemic Circulating IGF-1.Does single intramuscular application of autologous conditioned plasma influence systemic circulating growth factors?Salivary free insulin-like growth factor-i levels: effects of an acute physical exercise in athletes.Chromosome damage, apoptosis, and necrosis in exfoliated cells of oral mucosa from androgenic anabolic steroids users.Changes in the miRNA profile under the influence of anabolic steroids in bovine liver.Can Plasma Rich in Growth Factors Be Safe for Parental Use? A Safety Study in the Canine Model
P2860
Q21245429-963D415A-E008-40CC-81E7-52E49BCDDA5FQ27004552-528B97EB-3446-4634-ACEF-0951374CBFC1Q33614188-9387F041-82EA-4ED4-9C89-1A27F37AF21FQ34374459-42956596-8960-4E00-A70C-14396B7A72F8Q34972082-14A68593-C863-403C-8961-9559555204D7Q35659602-78630EC4-7DCE-4760-9170-AFDBC690F459Q35687198-C1555B05-6376-451D-9C96-FBA1AFBDE4B2Q37150322-1AA8566D-5442-44C5-9FCD-64585B1A6544Q37576419-506138C2-1C08-4413-ACC2-9D5C355D8A9AQ37805634-0492377D-ADF1-4E80-A1E7-2B174450027AQ37854803-20663D52-003A-46FC-AB9F-22F3B9886856Q37889236-B20A1B67-5434-4A2D-93F7-9DE5EE4E266EQ38589015-3B1B0F85-7C7D-405E-99D4-3775292CED25Q38738678-1955987A-0B6E-4726-B492-D17E4B70A107Q39121853-43491E87-A0E3-4DE4-A0C9-DF5FC946C745Q41727058-2B5E5C2C-355B-4CE1-835A-EE8A442EC5B2Q41940766-9F7F6822-6AD2-4C53-9D59-5D8EF004C637Q42545929-650B1919-031C-4349-9A1B-09D5193E213DQ51741751-A2D26CCA-9432-4B1A-A768-F98C1D622557Q53001344-E059F829-E43F-4D8F-AD90-E75E9994191BQ54393917-498A49D9-DBBC-46B6-8D28-98D6FFE00477Q58749611-8BDC6C04-0865-4BBA-AFC1-6E091133B93C
P2860
Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Doping with growth hormone/IGF ...... ietin: is there a cancer risk?
@ast
Doping with growth hormone/IGF ...... ietin: is there a cancer risk?
@en
type
label
Doping with growth hormone/IGF ...... ietin: is there a cancer risk?
@ast
Doping with growth hormone/IGF ...... ietin: is there a cancer risk?
@en
prefLabel
Doping with growth hormone/IGF ...... ietin: is there a cancer risk?
@ast
Doping with growth hormone/IGF ...... ietin: is there a cancer risk?
@en
P1476
Doping with growth hormone/IGF ...... ietin: is there a cancer risk?
@en
P2093
Grazia Graziani
Lucio Tentori
P304
P356
10.1016/J.PHRS.2007.01.020
P577
2007-02-03T00:00:00Z